Nurix Therapeutics CLO sells $134k in stock after option exercise
At a glance
- $NRIX today−4.84%last $14.73
- Vs industry peers−4.77 pts6-peer median −0.08% · far behind
- Since Oct 13−33.4%from the first trade after the story
- 52-week range18.5% above low$12.43 – $28.23
- Last reported profit$549.8Mquarter to Aug 31, 2026 · 10-Q
- In the headline$134KAmount
Nothing reported about nurix therapeutics across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.
Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.
What it means
- What to watch: In healthcare, the calendar is the catalyst: trial readouts, FDA dates and pricing rules drive most of the moves.
- How the stock is trading: $NRIX -4.84% in the latest session.
- Timing: It came out outside trading hours; the change shown is from the previous, already closed session. Market holidays are not detected.
Where the stock stands
Nurix Therapeutics ($NRIX) fell 4.84% to $14.73 in the latest session. Over the past month it is down 40.9%. It now sits 48% under the 52-week high of $28.23 and 19% above the year's low of $12.43. It has been a volatile year: the high was 2.3 times the low, so moves this size are not unusual for it.
What the filings say
In its latest report (10-Q, filed Oct 13, 2026), $NRIX earned $549.8M over the quarter to Aug 31, 2026 on revenue of $673.1M (+7342.9% QoQ). Operations brought in $447.1M of cash over the nine months to Aug 31, 2026; after capital spending, free cash flow was $442.8M. Total liabilities were $227.0M against $720.2M of cash on Aug 31, 2026. The company filed an 8-K — the form for material events — on Oct 13, the same day as this story; it is $NRIX's own account and the first thing to read. Figures are as filed with the SEC; the $NRIX page has the full statements.
How much coverage it is getting
Nothing new on Nurix Therapeutics has come through Wook's feeds in the last 30 days, so this is still the most recent story on it.
The bigger picture
In healthcare, the calendar is the catalyst — trial readouts, FDA decisions and pricing rules. One result can move a single drugmaker sharply; a policy change moves the whole aisle. Wook's supply-chain scanner shows no unusual stress in Health Care today.
What to watch next
The company's own filings are the primary source. Its latest SEC reports, including any filing on a material event, are on the $NRIX page, and they say what management has disclosed without a reporter in between. Reading how two or three outlets frame the same story is the quickest way to separate the facts from the angle. To run the numbers yourself, ask Wook AI above about $NRIX: its distance from the high, its last report, or how coverage has changed.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Investing.com published this on October 13, 2026. $NRIX has moved -33.44% ($22.13 to $14.73). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.
